HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Impact of Blood Pressure Visit-to-Visit Variability on Adverse Events in Patients With Nonvalvular Atrial Fibrillation: Subanalysis of the J-RHYTHM Registry.

Abstract
Background Blood pressure (BP) variability has reportedly been a risk factor for various clinical events. To clarify the influence of BP visit-to-visit variability on adverse events in patients with nonvalvular atrial fibrillation, a post hoc analysis of the J-RHYTHM Registry was performed. Methods and Results Of 7406 outpatients with nonvalvular atrial fibrillation from 158 institutions, 7226 (age, 69.7±9.9 years; men, 70.7%), in whom BP was measured 4 times or more (14.6±5.0 times) during the 2-year follow-up period or until occurrence of an event, constituted the study group. SD and coefficient of variation of BP values were calculated as BP variability. Thromboembolism, major hemorrhage, and all-cause death occurred in 110 (1.5%), 121 (1.7%), and 168 (2.3%) patients, respectively. When patients were divided into quartiles of systolic BP-SD (<8.20, 8.20-10.49, 10.50-13.19, and ≥13.20 mm Hg), hazard ratios (HRs) for all adverse events were significantly high in the highest quartile compared with the lowest quartile (HR, 2.00, 95% CI, 1.15-3.49, P=0.015 for thromboembolism; HR, 2.60, 95% CI, 1.36-4.97, P=0.004 for major hemorrhage; and HR, 1.85, 95% CI, 1.11-3.07, P=0.018 for all-cause death) after adjusting for components of the CHA2DS2-VASc score, warfarin and antiplatelet use, atrial fibrillation type, BP measurement times, and others. These findings were consistent when BP-coefficient of variation was used instead of BP-SD. Conclusions Systolic BP visit-to-visit variability was significantly associated with all adverse events in patients with nonvalvular atrial fibrillation. Further studies are needed to clarify the causality between BP variability and adverse outcomes in patients with nonvalvular atrial fibrillation. Registration URL: https://www.umin.ac.jp/ctr/; Unique Identifier: UMIN000001569.
AuthorsEitaro Kodani, Hiroshi Inoue, Hirotsugu Atarashi, Ken Okumura, Takeshi Yamashita, Toshiaki Otsuka, Hideki Origasa, J‐RHYTHM Registry Investigators *
JournalJournal of the American Heart Association (J Am Heart Assoc) Vol. 10 Issue 1 Pg. e018585 (01 05 2021) ISSN: 2047-9980 [Electronic] England
PMID33372541 (Publication Type: Journal Article, Observational Study, Research Support, Non-U.S. Gov't)
Chemical References
  • Anticoagulants
  • Platelet Aggregation Inhibitors
  • Warfarin
Topics
  • Aged
  • Ambulatory Care (methods, statistics & numerical data)
  • Analysis of Variance
  • Anticoagulants (administration & dosage, adverse effects)
  • Atrial Fibrillation (complications, diagnosis, drug therapy, mortality)
  • Blood Pressure Determination (methods, statistics & numerical data)
  • Cause of Death
  • Female
  • Hemorrhage (epidemiology, etiology)
  • Humans
  • Japan (epidemiology)
  • Male
  • Platelet Aggregation Inhibitors (administration & dosage, adverse effects)
  • Registries (statistics & numerical data)
  • Risk Assessment (methods)
  • Risk Factors
  • Thromboembolism (epidemiology, etiology, prevention & control)
  • Warfarin (administration & dosage, adverse effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: